# Dexamethasone in Refractory or First Relapsed Acute Myeloid Leukemia

> **NCT03765541** · PHASE3 · TERMINATED · sponsor: **University Hospital, Toulouse** · enrollment: 73 (actual)

## Conditions studied

- Relapsed or Refractory Acute Myeloid Leukemia

## Interventions

- **DRUG:** Dexamethasone
- **DRUG:** Amsacrine
- **DRUG:** Cytarabine
- **DRUG:** Azacitidine

## Key facts

- **NCT ID:** NCT03765541
- **Lead sponsor:** University Hospital, Toulouse
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-01-13
- **Primary completion:** 2024-05-31
- **Final completion:** 2024-05-31
- **Target enrollment:** 73 (ACTUAL)
- **Why stopped:** Despite a recruitment target that was not met, we managed to achieve more than 50% of inclusions and 33% of deaths, enabling us to carry out an initial analysis of the primary endpoint
- **Last updated:** 2025-04-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03765541

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03765541, "Dexamethasone in Refractory or First Relapsed Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT03765541. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*